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Wu WP, Chang CH, Chiu YT, Ku CL, Wen MC, Shu KH, Wu
MJ. A reduction of unilateral ureteral obstruction-induced renal
fibrosis by a therapy combining valsartan with aliskiren. Am J Physiol
Renal Physiol 299: F929–F941, 2010. First published August 4, 2010;
doi:10.1152/ajprenal.00192.2010.—The protective effect of combina-
tion therapy with valsartan and aliskiren against renal fibrosis remains
to be defined. This study was undertaken to examine the protective
effects of the combination of valsartan and aliskiren against renal
fibrosis induced by unilateral ureteral obstruction (UUO). Combina-
tion therapy with valsartan (15 mg·kg1 ·day1) and aliskiren (10
mg·kg1 ·day1), valsartan monotherapy (30 mg·kg1 ·day1), and
aliskiren monotherapy (20 mg·kg1 ·day1) all significantly amelio-
rated the increase in blood urea nitrogen and the degree of hydrone-
phrosis determined by the increase in weight and length of the
obstructed kidney. The dose titration study and blood pressure mea-
surement confirmed that the combination therapy provided a greater
benefit independent of the vasodilatory effect. There were no signif-
icant changes in serum levels of creatinine, sodium, and potassium in
UUO rats and any treatment groups. Combination therapy also atten-
uated UUO-related increases in the scores of tubular dilatation,
interstitial volume, interstitial collagen deposition, -smooth muscle
actin, the activation of ERK 1/2, the infiltration of monocytes/mac-
rophages, the mRNA expression of snail-1, and transforming growth
factor-1 to a greater extent compared with aliskiren or valsartan used
alone. The mRNA expression of renin and the (pro)renin receptor
significantly increased after UUO. Combination therapy and mono-
therapy of valsartan and aliskiren had a comparable enhancing effect
on the mRNA expression of renin, whereas all these treatments did not
affect the expression of the (pro)renin receptor. In conclusion, a direct
renin inhibitor in conjunction with an angiotensin II receptor blocker
exerts increased renal protection against renal fibrosis and inflamma-
tion during obstruction over either agent alone.
direct renin inhibitor; angiotensin II receptor blocker
THE ACTIVATION OF the renin-angiotensin-aldosterone system
(RAS) is an important contributing factor in the pathogenesis
of many cardiovascular and renal diseases (4, 6, 11). The
blockade of the RAS through an angiotensin-converting en-
zyme (ACE) inhibitor, angiotensin II receptor blocker (ARB),
or direct renin inhibitor (DRI), is a proven effective treatment
of hypertension, heart failure, diabetic nephropathy, and non-
diabetic renal diseases (5, 29, 39, 54). A dual therapy of ACE
inhibitor and ARB has been shown to significantly reduce
proteinuria and retard the progression of renal disease (21, 32,
35, 41–43). However, the risk of hyperkalemia with a combi-
nation therapy which combines the ACE inhibitor with ARB
has also shown to be higher than with the ACE inhibitor or
ARB used alone. Meanwhile, no matter whether the ACE
inhibitor or ARB is used alone or in combination therapy, they
all result in the increase in plasma renin activity (34, 51).
Renin, which controls the first and rate-limiting step of the
RAS, has been recognized since the late 1950s (16, 49) as a
preferred means for blocking the RAS. Direct renin inhibitors
block the activity of renin through the interaction with the
active site of the enzyme (7, 12, 52). The plasma renin activity
decreases with the use of DRIs (38). Aliskiren is the first oral
DRI which has been approved for the treatment of hyperten-
sion as monotherapy or in combination with other antihyper-
tensive medications by the US Food and Drug Administration
in March 2007 (9, 56). Given the success of an ACE inhibitor
and ARB in reducing morbidity and mortality among patients
with hypertension, diabetes mellitus, cardiac failure, nephrop-
athy, and atherosclerosis, DRI alone or a therapy combining
DRI with ARB may have potential benefits in the same disease
states (31, 45, 50). In an animal study, both perindopril and
aliskiren have shown to reduce blood pressure, albuminuria,
and structural injury in experimental diabetic nephropathy (25,
33). Aliskiren and perindopril both were equally effective in
reducing albuminuria and glomerulosclerosis in diabetic ani-
mals. Nevertheless, aliskiren had a better effect than perindo-
pril on reducing the magnitude of interstitial fibrosis. In an
AVOID (for Aliskiren in the eValuation of prOteinuria In
Diabetes) study, a combination therapy with aliskiren and
lorsartan resulted in 20% more proteinuria reduction than with
losartan monotherapy in adults with type 2 diabetes and ne-
phropathy. This effect was shown to be independent of blood
pressure control (4, 40).
Renal fibrosis is the final common pathological pathway of
most progressive renal disease regardless of the underlying
disease or the originating compartment (3, 13, 60). The model
of unilateral ureteral obstruction (UUO) generates progressive
renal fibrosis that is independent of hypertension or systemic
immune disease (8, 26). The obstructed kidney after UUO
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results in marked renal hemodynamic and metabolic changes.
It is followed by tubular injury and cell death by apoptosis or
necrosis, with interstitial macrophage infiltration (8, 27, 48,
55). Previous studies showed that ARBs or ACE inhibitors
could ameliorate renal tubulointerstitial fibrosis that was
caused by UUO (15, 20, 22–24). In this study, we investigate
the effect of a therapy combining aliskiren with valsartan,
referred to as combination therapy, on UUO-induced renal
fibrosis.
MATERIALS AND METHODS
Animals. The studies were conducted in male Sprague–Dawley rats
(200 g) obtained from the National Laboratory Animal Center
(Taipei, Taiwan). The experimental protocol was approved by the
Animal Care Committee of Taichung Veterans General Hospital. The
rats had free access to tap water and a standard rat diet.
Experimental design. The UUO rats underwent surgery as described
previously (58). The left kidney and ureter were exposed under intraperi-
toneal pentobarbital anesthesia via a flank incision. The left ureter was
ligated with 4-0 silk at two points and cut between the ligatures to prevent
retrograde urinary tract infection. Finally, the wound was closed in layers.
Sham animals underwent identical surgical procedures, but the left ureter
was simply manipulated.
The efficacy of aliskiren, valsartan, or combination therapy on UUO-
induced renal fibrosis was examined on days 7 and 14. In both experimental
sets, the rats were divided into the same seven groups: 1) sham-vehicle,
where animals underwent sham operations and were treated with vehicle
(n  10); 2) UUO-vehicle, where the animals underwent UUO but were
treated with vehicle (PBS; n  10); 3) UUO-valsartan, where the rats
underwent UUO and were treated with valsartan (15 mg·kg1·day1, n
10); 4) UUO-valsartan, where the rats underwent UUO and were treated with
valsartan (30 mg·kg1·day1, n  10); 5) UUO-aliskiren, where the rats
underwent UUO and were treated with aliskiren (10 mg·kg1·day1, n
10); 6) UUO-aliskiren, where the rats underwent UUO and were treated with
aliskiren (20 mg·kg1·day1, n 10); and 7) UUO-combination therapy,
where the rats underwent UUO and were treated with valsartan (15
mg·kg1·day1) and aliskiren (10 mg·kg1·day1, n  10).
The blood pressure of the tail artery of the rat was measured by
tail-cuff plethysmography (BP-98A; Softron, Tokyo, Japan) before
the start of drug treatment and before death. The day before death, a
24-h urine sample was collected from each rat in metabolic cages to
measure urinary protein excretion. All rats were killed under pento-
barbital sodium anesthesia on day 7 or day 14. Whole-blood samples
were collected from the tail vein of each rat for the measurement of
blood urea nitrogen (BUN), serum creatinine (Cr), serum sodium,
serum potassium, and plasma renin activity before harvesting.
Histopathological and immunohistochemical analysis. Bilateral kid-
neys from each rat were fixed in 4% formalin in PBS and embedded in
paraffin. Four-micrometer sections were stained with hematoxylin/eosin to
assess the grade of tubulointerstitial damage. A standard point counting
method, modified from previous reports, was used to determine the histo-
logical changes after UUO (58). Under high magnification (400), 20
nonoverlapping fields from each section of the renal cortex were photo-
graphed. A grid containing 100 (10 10) sampling points was superimposed
on each photograph. Points falling on glomerular structures or on large
vessels were excluded from the total count. The tubular dilatation score was
determined by the number of points overlying dilated tubular spaces and then
converted to a percentage. The staining scores of interstitial volume, intersti-
tial collagen deposition, and interstitial -smooth muscle actin (SMA) ex-
pression were assessed accordingly. The interstitial collagen deposition score
was determined by sirius staining, well established in our laboratory, as
described previously (58). The method used was the selective binding of
sirius red F3BA to all collagen proteins and Fast green FCF to noncollagen
proteins when both were dissolved in aqueous saturated picric acid. All
immunohistochemical studies were performed on paraffin-embedded sec-
tions as described previously (58). As a negative control, the primary
antibody was replaced with normal rabbit IgG, without staining. The matrix
score for -SMA expression in the renal cortical interstitium was determined
by procedures in accordance with previous reports (58). The monoclonal
antibody against human -SMA (1:200; EPOS System, Dako) was used.
To evaluate the infiltration of interstitial monocytes/macrophages,
a rabbit polyclonal antibody against ED-1 (1:200; Serotec, Oxford,
UK) was applied to the primary reaction, followed by a second
reaction with biotin-labeled anti-rabbit IgG (Vector Laboratories,
Burlingame, CA). Finally, a 3,3=-diaminobenzidine (DAB) reaction
was performed on the section using a kit (DakoCytomation), and
hematoxylin was used as the counterstain. The number of ED-1-
positive cells was determined from 10 randomly chosen 400 fields
within the same section of the kidney from an individual animal (58).
The average number of ED-1-positive cells from five separate rats was
calculated.
Quantitative determination of collagen and total protein. The
quantitative measurement of collagen and total protein content in
formalin-fixed, paraffin-embedded tissue sections was preformed as
described previously (58). The method used the selective binding of
sirius red F3BA to collagen protein and Fast green FCF to noncolla-
gen protein when both were dissolved in aqueous saturated picric acid.
When the dye was eluted from the tissue sections with sodium
hydroxide-methanol, the absorbances of 540 and 605 nm were deter-
mined for sirius red F3BA and Fast green FCF-binding proteins. The
absorbances provided a relative measurement of collagen/total protein
(g/mg) quantity. Because the determination of collagen was relative
to the concentration of protein per milligram in each tissue section, the
thickness or the area of histological preparation was not a significant
factor.
Western blot analysis. The expression of type IV collagen and
-SMA proteins in cell lysates and kidney tissue was analyzed by
Western blotting as described previously (57, 58). The cell lysates (20
g protein) were separated on 10% SDS-polyacrylamide gels. The
proteins were electroblotted onto a nitrocellulose membrane (Amer-
sham, Piscataway, NJ). Filters were incubated overnight at 4°C with
antibodies directed against the type IV collagen (Dako), -SMA
(Dako), or actin (Santa Cruz Biotechnology) and then incubated with
a secondary antibody.
RT-PCR. Total RNA isolation, reverse transcription of the RNA,
and all PCR experiments were performed. Total RNA was prepared
from a kidney tissue by using TRIzol reagent (Invitrogen, Carlsbad,
CA) and was quantified by the determination of ultraviolet absorbance
at 260 nm. The first strand of cDNA was synthesized using 2 g RNA
in 20 l of reaction buffer by a reverse transcription using AMV-RT
(Promega, Madison, WI) and random primers, at 42°C for 30 min.
The PCR was performed using a standard PCR kit on 1-l aliquots of
cDNA and HotStarTaq polymerase (Qiagen, Valencia, CA) with
gene-specific primer pairs. About 20–25 cycles at 94°C for 1 min,
55°C for 1 min, and 72°C for 1 min for amplification in a linear range
were used and followed by a final extension step at 72°C for 7 min.
The products of PCR were size-fractionated on agarose gels and
detected by ethidium bromide staining. After quantification of band
intensities using densitometry, the relative steady-state level of
mRNA was calculated after normalizing to –actin. The sequences of
primer sets were specified as follows: Snail, 5=-CAC TAT GCC GCG
CTC TTT C-3= (sense) and 5=-GGT CGT AGG GCT GCT GGA A-3=
(antisense); transforming growth factor-1 (TGF-1), 5=-CCT GAG
TGG CTG TCT TTT GAC G-3= (sense) and 5=-AGT GAG CGC TGA
ATC GAA AGC-3=(antisense); renin, 5=-ATC TTT GAC ACG GGT
TCA GC-3= (sense) and 5=-CAC AGT GAT TCC ACC CAC AG-
3=(antisense); prorenin receptor, 5=-TTC TGA ACT GCA AGT GCT
GCA T-3= (sense) and 5=-CTG CCA GCT CCA GTG AAT ACA
AG-3=(antisense); and –actin, 5=-CAG CTG AGA GGG AAA TCG
TG-3= (sense) and 5=-CGT TGC CAA TAG TGA TGA CC-3=
(antisense).
F930 ALISKIREN AND VALSARTAN REDUCE RENAL FIBROSIS
AJP-Renal Physiol • VOL 299 • NOVEMBER 2010 • www.ajprenal.org
ELISA of TGF-. Extracts were made from kidney tissue from
control and 14 days UUO rats with or without valsartan and aliskiren
treatment. Equal amounts of protein were analyzed for the presence of
TGF- using a TGF- ELISA kit (R&D Systems, Minneapolis, MN).
Each sample was assayed in duplicate.
Statistical analysis. All data were expressed as means  SE.
Statistical calculations were performed using SPSS software (SPSS,
Chicago, IL). One-way analysis of variance and multiple comparison
tests were used to determine the statistical significance. Statistical
significance was defined as a P value 	0.05.
RESULTS
Effect of each treatment on changes in kidney weight, kidney
length, and cross-section morphological finding on UUO rats.
As shown in Fig. 1, both the weight and length of the ob-
structed kidney increased significantly after UUO compared
with the sham-operated kidney and contralateral nonobstructed
kidney (Fig. 1, A and B) (P 	 0.001). Compared with the
vehicle group, the 30 mg·kg1 ·day1 valsartan group signif-
icantly attenuated the increase of obstructed kidney length by
10.9% on day 7 and 13.6% on day 14 (both P	 0.05, Fig. 1A),
and the reduction was similar to that in the 20 mg·kg1 ·day1
aliskiren group (10.2% on day 7, P 	 0.05 and 13.0% on
day14, P  0.058). In the combination therapy with 15
mg·kg1 ·day1 valsartan and 10 mg·kg1 ·day1 aliskiren,
the reduction was better (19.5% on day 7 and 28.6% on day14)
than that obtained by either valsartan or aliskiren on day 7 or
day 14 (all P 	 0.05). Monotherapy with 15 mg·kg1 ·day1
valsartan or 10 mg·kg1 ·day1 aliskiren failed to reduce the
increase in obstructed kidney length.
Being consistent with the data on obstructed kidney
length, the increase in kidney weight was reduced in the
valsartan group (18.5% on day 7 and 19.9% on day 14, both
P 	 0.005, Fig. 1B), and the reduction was also significant
in the aliskiren group (18.0% on day 7 and 18.8% on day 14,
both P 	 0.005) and in the combination therapy group
(34.4% on day 7 and 36.1% on day14, both P 	 0.005). In
the meantime, the reduction of kidney weight in the com-
bination therapy group was significantly better than in either
the valsartan or the aliskiren group on day 7 or day 14 (all
P 	 0.05), whereas monotherapy with 15 mg·kg1 ·day1
valsartan or mg ·kg1 ·day1 aliskiren failed to reduce the
increase in obstructed kidney weight.
As shown in Fig. 2, monotherapy with 30 mg·kg1·day1
valsartan and 20 mg·kg1·day1 aliskiren significantly and sim-
ilarly ameliorated the change in the cross-sectional morphological
changes in the obstructed kidney on days 7 and 14 after UUO.
Combination therapy with 15 mg·kg1·day1 valsartan and 10
mg·kg1·day1 aliskiren ameliorated these morphological changes
to a greater extent than monotherapy with 30 mg·kg1·day1 val-
sartan and 20 mg·kg1·day1. aliskiren.
Effect on blood pressure in UUO rats. As shown in Fig. 3A,
the blood pressure of rats treated by UUO for 14 days
was significantly higher than that of control normal rats.
Combination therapy with valsartan (15 mg·kg1 ·day1)
and aliskiren (10 mg·kg1 ·day1) and valsartan mono-
therapy (30 mg·kg1 ·day1) and aliskiren monotherapy (20
mg·kg1 ·day1) all slightly reduced the blood pressure of
rats. At both 7- and 14-day UUO examination, the blood
pressure of rats was comparable among the groups of
combination therapy with valsartan (15 mg·kg1 ·day1)
and aliskiren (10 mg·kg1 ·day1) and valsartan monotherapy
(30 mg · kg1 · day1) and aliskiren monotherapy (20
mg·kg1·day1).
Effect on BUN, serum Cr, serum sodium, serum potassium,
and 24-h proteinuria in UUO rats. As shown in Fig. 3B, BUN
significantly increased in rats subjected to UUO for 7 and 14 days.
Combination therapy with valsartan (15 mg·kg1·day1) and
aliskiren (10 mg·kg1·day1) and valsartan monotherapy (30
mg·kg1·day1) and aliskiren monotherapy (20 mg·kg1·day1)
all significantly ameliorated the increase in BUN of rats with
UUO. Combination therapy with valsartan (15 mg·kg1·day1)
and aliskiren (10 mg·kg1·day1) provided a greater reduction of
BUN than monotherapy with valsartan (30 mg·kg1·day1) and
aliskiren (20 mg·kg1·day1).
Fig. 1. Blockade of the renin-angiotensin-aldosterone system (RAS) significantly
blunted the increase in obstructed kidney weight and length on day 7 and 14 after
unilateral ureteral obstruction (UUO). Values are means SE; n 5/group. *P	
0.05 vs. vehicle-treated rats after the same day of UUO. **P 	 0.005 vs.
vehicle-treated rats after the same day of UUO. 
P 	 0.05 vs. valsartan (30
mg·kg1 ·day1)- or aliskiren (20 mg·kg1 ·day1)-treated rats after the same
day of UUO.
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Unlike BUN, the serum Cr, serum sodium, serum potassium,
and 24-h proteinuria were not significantly affected by UUO
and any drug treatment (Fig. 3, C–F).
Combination therapy with valsartan and aliskiren attenu-
ated histological changes in the obstructed kidney induced by
UUO. Figure 4 shows a representative histological finding
by hematoxylin-eosin staining, -SMA staining, and sirius
staining on day 14 of UUO in kidney tissue of UUO rats
treated by vehicle, valsartan, aliskiren, and combination
therapy. The obstructed kidney treated by the vehicle
showed severe tubular dilatation, tubular atrophy, and wid-
ened interstitial space with a greater number of interstitial
cells and infiltrating leukocytes. These changes were ob-
served in the whole cortex, although the degree of severity
was not homogeneously distributed. The administration of
valsartan significantly attenuated the tubulointerstitial dam-
age after UUO (Fig. 4C). The scores of tubular dilatation
after UUO were significantly reduced by 30.1% on day 7
and 20.6% on day 14 (from 26.6 to 18.6 and from 36.0 to
28.6%, respectively, both P 	 0.05, Fig. 5A). The effect
resulting from the tubular dilation score reduction of
aliskiren was similar (30.1% on day 7 and 20.0% on day 14)
with valsartan (P  1.0, Fig. 4D). By contrast, there was a
significantly better effect on the reduction of the tubular
dilatation score by combination therapy (58.6% on day 7
and 38.9% on day 14, P 	 0.05, Fig. 4E).
The administration of valsartan blunted the score increase of
the interstitial volume by 20.6% on day 7 and by 19.5% on day
14 (from 33.0 to 26.2 and from 41.0 to 33.0%, respectively,
both P	 0.05, Fig. 5B). The effect of aliskiren was also similar
(19.4% on day 7 and 19.5% on day 14) for valsartan. Surpris-
ingly, an effect using the combination therapy (38.2% on day
7 and 34.1% on day 14, P	 0.05) was found to be significantly
better than that using either valsartan or aliskiren alone.
Combination therapy with valsartan and aliskiren decreased
expression of -SMA and collagen in the obstructed kidney
induced by UUO. We examined the effect of blockage of the
RAS on interstitial myofibroblasts characterized by the expres-
sion of -SMA. This contrasted with a high number of cells
with -SMA expression surrounding the peritubular and peri-
glomerular spaces that developed in Sprague-Dawley rats after
UUO (Fig. 4G). Valsartan significantly reduced the score of
-SMA expression in the cortical interstitium of UUO rats by
15.3% on day 7 and by 14.1% on day 14 (from 27.4 to 23.2%
and from 35.4 to 30.4%, respectively, both P 	 0.05, Figs. 4H
and 5C). The effect of aliskiren was found to be similar (16.8%
on day 7 and 13.0% on day 14) to valsartan (Fig. 4I). By
contrast, the combination therapy (31.4% on day 7 and 27.7%
on day 14, P 	 0.05) was shown to be significantly better than
either valsartan or aliskiren alone (Fig. 4J).
The interstitial collagen deposition of the obstructed kidney
was significantly increased on day 7 after UUO compared with
that of contralateral kidneys (Fig. 4L). The score of interstitial
collagen deposition by sirius staining also showed improve-
ment by the blockage of the RAS (Fig. 5D). The valsartan
administration significantly blunted the increase in the score of
interstitial collagen deposition of the obstructed kidney by
26.9% on day 7 and by 15.4% on day 14 (from 26.8 to 19.6 and
from 37.6 to 31.8%, respectively, both P	 0.05, Fig. 4M). The
effect of aliskiren was also similar (27.6% on day 7 and 12.8%
on day 14) to valsartan (Fig. 4N). Compared with aliskiren and
valsartan, the combination therapy results in a much better
effect (48.5% on day 7 and 29.3% on day 14, P 	 0.05) than
either valsartan or aliskiren used alone (Fig. 4O).
Western blot analyses of the kidney tissue extracts also
revealed that the expression of collagen IV and -SMA in the
obstructed kidney was significantly increased. Combination
therapy and monotherapy with valsartan and aliskiren signifi-
Fig. 2. Cross section of an obstructed kidney. (Effect of RAS system blockade on UUO-induced renal fibrosis in rats is shown).
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Fig. 3. Effect on blood pressure, blood urea nitrogen (BUN), serum Cr, serum sodium, serum potassium, and 24-h proteinuria of UUO rats treated by valsartan
(30 mg ·kg1 · day1), aliskiren (20 mg ·kg1 · day1), and combination therapy with valsartan (15 mg ·kg1 · day1) and aliskiren (10 mg ·kg1 · day1). Values
are means  SE; n  5/group. *P 	 0.05 vs. vehicle-treated rats after the same day of UUO. **P 	 0.005 vs. vehicle-treated rats after the same day of UUO.
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cantly attenuated the increase in collagen IV and -SMA
expression (Fig. 6).
We also determined the amounts of collagen and total
protein content in the kidney tissue sections. Compared with
the control kidney (12.5  1.9 g/mg) on day 7, the values
were significantly higher (P 	 0.005) in the obstructed kidney
(26.2 2.4 g/mg on day 7 and 34.0 4.1 g/mg on day 14).
Valsartan effectively reduced the amounts of collagen by
14.7% on day 7 and by 16.3% on day 14 (from 26.2  2.4 to
22.3  1.7 and from 34.0  4.1 to 28.5  1.3 g/mg,
respectively, P 	 0.05 on day 14, Fig. 5E). The effect of
aliskiren was found to be similar (14.1% on day 7 and 14.5%
on day 14) to valsartan. Meanwhile, the combination therapy
(27.1% on day 7 and 21.9% on day 14) had a better effect than
either valsartan or aliskiren used alone, but it was not signifi-
cant.
Combination therapy with valsartan and aliskiren reduced
infiltration of monocytes/macrophages and phosphorylation of
ERK 1/2 in the obstructed kidney induced by UUO. The
infiltration of ED-1-positive monocytes/macrophages was
present as reported previously (Fig. 4Q) (58). Valsartan pre-
treatment resulted in a mild reduction in the number of infil-
trating ED-1-positive cells by 9.4% on day 7 and 6.5% on day
14 (from 25.6 to 23.2 and from 33.8 to 31.6, respectively, Figs.
4R and 5F). The effect of aliskiren was better than that of
valsartan (18.0% on day 7 and 16.6% on day 14, both P 	
0.05, Fig. 4S). Interestingly, the combination therapy (39.8%
on day 7 and 35.8% on day 14) showed the greatest inhibitory
effect compared with either valsartan or aliskiren (both P 	
0.05, Fig. 4T).
The Western blot analyses of the kidney tissue extracts
showed that the ERK 1/2 pathway was activated after UUO as
indicated in previous reports (Fig. 6). Both aliskiren and
valsartan could reduce the activation of ERK 1/2. Once again,
the combination of these two drugs inhibited the phosphoryla-
tion of ERK 1/2 to a greater extent than each drug used alone.
Effect of each treatment on mRNA expression of snail, TGF -1,
renin, and (pro)renin receptor in the obstructed kidney. As shown in
Fig. 7, the mRNA expression of snail, TGF-1, renin, and
(pro)renin receptor were all increased in the obstructed kidney
14 days after UUO. Combination therapy and monotherapy
with valsartan and aliskiren all exhibited a significantly ame-
Fig. 4. Blockade of RAS attenuated the tubulointerstitial change of the obstructed kidney on day 14 after UUO by different kinds of staining. Shown are
representative micrographs of hematoxylin–eosin (H&E) staining (A–E), -smooth muscle actin (-SMA) staining (F–J), sirius staining (K–O), and ED-1
staining (P–T) in kidney tissue of normal rats that received sham operation (A, F, K, P) or rats that received UUO and were treated with vehicle (B, G, L, Q),
valsartan (30 mg ·kg1 · day1; C, H, M, R), aliskiren (20 mg ·kg1 · day1; D, I, N, S), and combination therapy with valsartan (15 mg ·kg1 · day1) and aliskiren
(10 mg ·kg1 · day1; E, J, O, T). Bar  50 m.
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Fig. 5. Blockade of RAS attenuated the scores of tubulointerstitial damage of the obstructed kidney on day 7 and 14 after UUO. The scores for tubular
dilatation (A), interstitial volume (B), -SMA expression (C), interstitial collagen deposition (D), collagen/total protein (g/mg; E), and ED-1-positive
cells of the obstructed kidney on days 7 and 14 after UUO (F). Values are means  SE; n  5/group.*P 	 0.05 vs. vehicle-treated rats after the same
day of UUO. **P 	 0.005 vs. vehicle-treated rats after the same day of UUO. 
P 	 0.05 vs. valsartan (30 mg · kg1 · day1)- or aliskiren (20
mg · kg1 · day1)-treated rats after the same day of UUO. 

P 	 0.005 vs. valsartan- or aliskiren-treated rats after the same day of UUO.
F935ALISKIREN AND VALSARTAN REDUCE RENAL FIBROSIS
AJP-Renal Physiol • VOL 299 • NOVEMBER 2010 • www.ajprenal.org
Fig. 6. Western blot showed that combination therapy has better efficacy than aliskiren or valsartan to block the increase of collagen IV and the de novo expression of
-SMA and phospho-ERK 1/2 on day 14 after UUO. The same blot was stripped and reprobed with actin to confirm equal loading. Western blot results (A) and
quantitative data (B-E) are presented. Values are means  SE; n 3. V, valsartan (30 mg·kg1 ·day1); A, aliskiren (20 mg·kg1 ·day1); V
A, valsartan (15
mg·kg1 ·day1) and aliskiren (10 mg·kg1 ·day1). *P	 0.05 vs. vehicle-treated rats after the same day of UUO. **P	 0.005 vs. vehicle-treated rats after the same
day of UUO. 
P 	 0.05 vs. valsartan (30 mg·kg1 ·day1)- or aliskiren (20 mg·kg1 ·day1)-treated rats after the same day of UUO.
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Fig. 7. Expression of snail 1 and TGF-1, renin, and (pro)renin receptor in sham-operated kidneys, UUO kidneys treated with vehicle, valsartan, aliskiren, and
combination therapy on day 14. Representative RT-PCR (A) and quantitative determination of mRNA (B–E) showed the expression in the obstructed kidney after
various treatments. Values are means  SE; n 3. Abbreviations for treatments is as in Fig. 6. *P 	 0.05 vs. vehicle-treated rats after the same day of UUO.
**P 	 0.005 vs. vehicle-treated rats after the same day of UUO. 
P 	 0.05 vs. valsartan (30 mg ·kg1 · day1) or aliskiren (20 mg ·kg1 · day1)-treated rats
after the same day of UUO.
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liorating effect on the mRNA expression of snail and TGF-1
in the obstructed kidney induced by UUO. Again, combination
therapy showed a greater beneficial effect on the mRNA
expression of snail and TGF-1 than monotherapy with val-
sartan and aliskiren. Combination therapy and monotherapy
with aliskiren had a comparable greater increase in renin
mRNA expression than valsartan monotherapy, whereas all
these treatments did not affect the expression of the (pro)renin
receptor.
ELISA of TGF- in the obstructed kidney induced by UUO.
Being consistent with the data on mRNA expression, TGF-
ELISA showed that TGF- was increased 6.1-fold in the
kidney tissue of 14-day UUO rats compared with control
normal rats (2.26  0.41 vs. 0.37  0.04, P 	 0.05).
Combination therapy with valsartan (15 mg·kg1 ·day1)
and aliskiren (10 mg·kg1 ·day1) and valsartan mono-
therapy (30 mg·kg1 ·day1) and aliskiren monotherapy (20
mg·kg1 ·day1) all significantly ameliorated the increase
in TGF- in obstructed kidney tissues. Combination therapy
with valsartan (15 mg·kg1 ·day1) and aliskiren (10
mg·kg1 ·day1) provided a greater reduction of TGF-
than monotherapy with valsartan (30 mg·kg1 ·day1) and
aliskiren (20 mg·kg1 ·day1) (0.76  0.04 vs. 1.12  0.10
and 1.18  0.07, P 	 0.05).
Combination therapy with valsartan and aliskiren changes
plasma renin activity. Plasma renin activity was significantly
higher (P 	 0.05) in the UUO kidney (10.7  3.0
ng ·ml1 ·h1 on day 7 and 12.7  1.6 ng ·ml1 ·h1 on day
14) compared with the control normal kidney (5.7  1.5
ng ·ml1 ·h1 on day 7 and 5.5  1.6 ng ·ml1 ·h1 on day
14, Fig. 8). The valsartan group had a higher level of plasma
renin activity than the UUO group by 34.0% on day 7 and
35.4% on day 14 (from 10.7  3.0 to 14.3  4.3 ng·ml1·h1
on day 7 and from 12.7 1.6 to 17.1 3.0 ng·ml1·h1 on day 14,
P 	 0.05 on day 14). The effect of aliskiren was the reverse; the
plasma renin activity level was lower than in UUO rats treated with
vehicle by 83.7% on day 7 and 85.8% on day 14 (from 10.7  3.0
to 1.7  1.1 ng·ml1·h1 on day 7 and from to 1.8  0.5
ng·ml1·h1 on day 14, both P	 0.005). The combination therapy
group also had a lower plasma renin activity level than the UUO
group by 50.8% on day 7 and 50.6% on day 14 (from 10.7 3.0 to
5.3 1.8 ng·ml1·h1 on day 7 and from 12.7 1.6 to 6.31.6
ng·ml1·h1 on day 14, both P 	 0.05).
DISCUSSION
The results presented in this study are believed to be the first
to demonstrate a protective effect of the combination therapy
using valsartan and aliskiren, a DRI, on renal fibrosis induced
by UUO. The combination of ARB and DRI has also shown
superior efficacy in protecting against renal fibrosis in models
of diabetic nephropathy and hypertensive cardiac and renal
injury in mice (10, 59). The rationale for the combination
therapy of valsartan and aliskiren is based on the different
mechanisms of actions of these two drug classes. The mecha-
nisms of renal fibrosis involve several contributory steps. Each
RAS inhibitor has significantly, but not completely, renopro-
tective effects on renal fibrosis. Thus appropriate combinations
of the RAS inhibitors may have a better effect on renal fibrosis
theoretically. The renoprotective effect of the combination
therapy with an ACE inhibitor and ARB has been reported in
animal and clinical studies (21, 28). The ACE inhibitor has
been well known to decrease the formation of angiotensin II
and thus attenuates renal fibrosis in obstructive uropathy (23).
There were also several combination studies with ACE inhib-
itors which showed very good renoprotective effects in a rat
model of renal fibrosis induced by UUO (28). One study
showed that mycophenolate mofetil (MMF) and the ACE
inhibitor lisinopril attenuated the progression of the fibrogenic
process of UUO in an equivalent manner (14). The combina-
tion of both drugs did not show further improvement in the
collagen content. Another study of UUO showed that parical-
citol blocked renin induction in the absence or presence of
trandolapril (53). The combination therapy had additional ef-
ficacy in retarding renal scar formation during obstructive
nephropathy. However, the risk of hyperkalemia, cough, and
an insufficient response of the ACE inhibitor limits its clinical
use (2). The insufficient response of the ACE inhibitor is
caused by an incomplete blockade of the angiotensin convert-
ing enzyme after chronic ACEI inhibitor treatment or the
generation of angiotensin II by ACE-independent pathways
such as chymase (17, 37). On the other hand, a number of
studies have shown that treatment with ARB is effective in
reducing the rate of renal disease progression (5, 20, 30). ARB
showed better tolerability than the ACE inhibitor, with less
cough, angioedema, and hyperkalemia (2, 18). Besides, ARB
may result in an incomplete blockage of the actions of angio-
tensin II mediated through the angiotensin II type 1 receptor
(1). In the AVOID trial, the overall rate of hyperkalemia was
similar between the aliskiren and the placebo groups (39).
However, the rate of hyperkalemia was slightly higher when
aliskiren was administered concomitantly with valsartan (4%)
compared with aliskiren monotherapy (2%) or valsartan mono-
therapy (2%) (40). In fact, the combination therapy of DRI and
Fig. 8. Plasma renin activity of the obstructed kidney of UUO rats treated by
valsartan (30 mg·kg1 ·day1), aliskiren (20 mg·kg1 ·day1), and combination
therapy with valsartan (15 mg·kg1 ·day1) and aliskiren (10 mg·kg1 ·day1).
Values are means SE; n 5/group. *P	 0.05 vs. vehicle-treated rats after the
same day of UUO. **P 	 0.005 vs. vehicle-treated rats after the same day of
UUO. 
P 	 0.05 vs. valsartan or aliskiren-treated rats after the same day
of UUO.
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ARB, similar to the monotherapy of DRI and ARB, did not
exert any effect on serum potassium in this study.
Hypertension and albuminuria are common in diabetic pa-
tients and are important risk factors for chronic kidney disease
and renal fibrosis. Aliskiren reduced albuminuria and glomer-
ulosclerosis in the rat model of advanced diabetic nephropathy
by the blood pressure-independent pathway and also attenuated
tubulointerstitial fibrosis to a greater extent than did perindopril
(25). Aliskiren did not reduce the systemic blood pressure as
much as did perindopril, but both compounds were equally
effective in reducing albuminuria and glomerulosclerosis in
diabetic animals. Indeed, UUO and any treatment group did not
affect the 24-h proteinuria in this study. Since both valsartan
and aliskiren are antihypertensive drugs, the information of
blood pressure is very critical to correctly interpret the results.
Comparable reduction of blood pressure in all treatment groups
in this study confirmed that the greater beneficial effect of
combination therapy is independent of the vasodilatory effect.
Besides, we also performed the titration study to provide
justification for the medication dosage.
DRI has been proven to be beneficial in diabetic and nondiabetic
renal disease.(31, 45, 50). Theoretically, the DRI could decrease both
angiotensin II formation and plasma renin activity despite that DRI
may also incompletely block the activity of renin through interaction
with an active site of the enzyme (52). In this study, the degree of
hydronephrosis determined by kidney weights and lengths, and the
scores for tubular dilatation, interstitial volume, interstitial collagen
deposition, and -SMA expression were all decreased under the
blockage of valsartan, aliskiren, or the combination therapy. Western
blot analysis also showed that the blockage of the RAS system could
reduce the activation of ERK, as well as the expression of type IV
collagen and -SMA. In addition, the RT-PCR data also proved that
the treatment with valsartan and aliskiren could inhibit the expression
of snail-1 and TGF-1. Especially, aliskiren has similar effects on
inhibition of renal fibrosis compared with valsartan, whereas the
therapy of combining these two classes of drugs showed a signifi-
cantly better effect than with monotherapy of either valsartan or
aliskiren on renal fibrosis induced by UUO. Similar to previous
reports, our study also found that plasma renin activity was elevated
in the UUO group and even higher in the valsartan group (17). By
contrast, the aliskiren decreased the plasma renin activity level, which
was reduced to the level near the sham-operated group, when
aliskiren was added with valsartan for dual inhibition.
The binding of renin and prorenin to the (pro)renin
receptor induces an intracellular signal with phosphoryla-
tion of serine and tyrosine residues which are associated
with an angiotensin II that is an independent activation of
the mitogen-activated protein kinases, In fact, angiotensin II
can also activate the ERK 1/2 pathway which is known to be
involved in cell hypertrophy and proliferation (36). In this
study, we found that the activation of ERK 1/2 was ame-
liorated by the combination therapy and monotherapy with
valsartan and aliskiren in a similar pattern to the histological
index of renal fibrosis. As predicted, our results showed that
the mRNA expression of renin and the (pro)renin receptor
significantly increased after UUO. Aliskiren monotherapy
and combination therapy of aliskiren and valsartan had a
comparable greater increase in renin mRNA expression than
valsartan monotherapy. However, we found that all these
treatments did not affect the expression of the (pro)renin
receptor in the obstructed kidney tissues. (Pro)renin receptor
activation also has been shown to stimulate profibrotic
pathways in the kidney that are independent of angiotensin
II and therefore unaffected by ARBs and ACE inhibitors and
presumably unaffected by DRI (19). Although the reactive
increase in pro(renin) secretion with the DRI which poten-
tially activates the fibrotic pathways, the feedback-suppres-
sive mechanism of the (pro)renin receptor expression by a
high concentration of pro(renin) provides one possible ex-
planation for our findings (44). DRI may also provide
additional protection over other RAS inhibitors by interfer-
ing with the enhanced catalytic activity of (pro)renin after
the binding of these molecules to the (pro)renin receptor
(47).
Ureteral obstruction causes the infiltration of the kidney by
monocytes/macrophages. The tubulointerstitial influx of in-
flammatory cells has been observed in many forms of chronic
kidney disease, and persistent inflammation in the kidney is
thought to contribute to the development of tubulointerstitial
fibrosis with functional impairment (46). The role of macro-
phages in inducing tissue injuries by releasing reactive oxygen
species, nitric oxide, complement factors, and proinflammatory
cytokines, or even an opposite role in resolution of inflamma-
tion or assisting regeneration has also been reported (46). Our
experiments indicate that the infiltration of monocytes/macro-
phages in the obstructed kidney was significantly reduced by
the administration of the DRI, but not by the ARB.
One the whole, our results demonstrate compelling evidence
that a DRI in conjunction with an ARB provides increased
renal protection against renal fibrosis and inflammation during
obstruction over either agent alone.
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